The interaction between cannabis use and the Val158Met polymorphism of the COMT gene in psychosis: A transdiagnostic meta – analysis
T. Vaessen, Lea de Jong, A. T. Schäfer, Thomas Damen, Aniek Uittenboogaard, Pauline Krolinski, C. V. Nwosu, F. M. E. Pinckaers, I. Rotee, A. P. W. Smeets, Ayşegül Ermiş, J. Kennedy, D. Nieman, A. Tiwari, Jim van Os, Marjan Drukker
PLoS One February 14, 2018 DOI: 10.1371/journal.pone.0192658 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Meta-analysis Peer reviewed |
|---|---|
| Topics | Cannabis |
| Key findings | The interaction between cannabis use and COMTVal158Met was statistically significant only in case-only studies (OR 1.45, 95% CI 1.05–2.00, Met/Met risk genotype), but not in studies with dichotomous or continuous psychosis outcomes. The authors conclude that evidence for this gene–environment interaction remains unconvincing, partly because case-only designs tend to overestimate true effects. |
Abstract
Background: Neither environmental nor genetic factors are sufficient to predict the transdiagnostic expression of psychosis. Therefore, analysis of gene-environment interactions may be productive.
Objective: A meta-analysis was performed using papers investigating the interaction between cannabis use and catechol-O-methyl transferase (COMT) polymorphism Val158Met (COMTVal158Met). Data sources PubMed, Embase, PsychInfo. Study eligibility criteria All observational studies assessing the interaction between COMTVal158Met and cannabis with any psychosis or psychotic symptoms measure as an outcome. Study appraisal and synthesis methods A meta-analysis was performed using the Meta-analysis of Observational Studies in Epidemiology guidelines and forest plots were generated. Thirteen articles met the selection criteria: 7 clinical studies using a case-only design, 3 clinical studies with a dichotomous outcome, and 3 studies analysing a continuous outcome of psychotic symptoms below the threshold of psychotic disorder. The three study types were analysed separately. Validity of the included studies was assessed using "A Cochrane Risk of Bias Assessment Tool: for Non-Randomized Studies of Interventions".
Results: For case-only studies, a significant interaction was found between cannabis use and COMTVal158Met, with an OR of 1.45 (95% Confidence Interval = 1.05–2.00; Met/Met as the risk genotype). However, there was no evidence for interaction in either the studies including dichotomous outcomes (B = -0.51, 95% Confidence Interval -1.72, 0.70) or the studies including continuous outcomes (B = -0.04 95% Confidence Interval -0.16–0.08). Limitation A substantial part of the included studies used the case-only design, which has lower validity and tends to overestimate true effects.
Conclusion: The interaction term between cannabis use and COMTVal158Met was only statistically significant in the case-only studies, but not in studies using other clinical or non-clinical psychosis outcomes. Future additional high quality studies might change current perspectives, yet currently evidence for the interaction remains unconvincing.
Comparable studies
Other systematic reviews and meta-analyses on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Effects of cannabis use on outcomes of psychotic disorders: systematic review People with psychotic disorders, as examined in 13 longitudinal studies | 2008 | Systematic review | |
| The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample Patients with established schizophrenia (meta-analysis: 572) and patients with... | 2010 | Meta-analysis and cross-sectional observational study | n = 700 |
| Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review | 2020 | Systematic review | |
| Neuroimaging in cannabis use: a systematic review of the literature Cannabis users and controls in neuroimaging studies | 2009 | Systematic review | |
| Human Laboratory Studies on Cannabinoids and Psychosis. Healthy human subjects and individuals with schizophrenia | 2016 | Systematic review |
Citations in the library
Cited by 11
- Sustratos genéticos de la psicosis asociada al cannabis Revista Española de Drogodependencias December 30, 2022
- Genetic substrates of cannabis-associated psychosis Revista Española de Drogodependencias December 30, 2022
- Cannabis and psychopathology: 2024 Snapshot of a meandering journey Indian Journal of Psychiatry March 1, 2025
- The Role of Cannabis in the Development of Psychosis. Turk psikiyatri dergisi = Turkish journal of psychiatry 2024
- A systematic evidence map of the association between cannabis use and psychosis-related outcomes across the psychosis continuum: An umbrella review of systematic reviews and meta-analyses. Psychiatry Research November 1, 2023
and 6 more in the library
Cites 6
- Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry 2003
- Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study BMJ March 1, 2011
- COMT Val158Met moderation of cannabis‐induced psychosis: a momentary assessment study of ‘switching on’ hallucinations in the flow of daily life Acta Psychiatrica Scandinavica September 19, 2008
- Chronic adolescent exposure to Δ-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes. Neuropsychopharmacology October 2010
- Adolescent Cannabis Use, Psychosis and Catechol-O-Methyltransferase Genotype in African Americans and Caucasians Psychiatric Quarterly July 25, 2009
and 1 more in the library